- About Us
- Insight by Design
- Knowledge Center
How long does it take to ascertain the correct diagnosis? Which doctors will patients see, and who will they be referred to next? These seemingly direct questions are often all too complicated in rare disease. If we could better educate providers about disease symptoms and triggers, perhaps patients could be diagnosed sooner, and begin appropriate treatment sooner as well. That’s exactly what the International Pemphigoid and Pemphigus Foundation (IPPF) had in mind. Read the full post to learn how we helped!
What is patient journey? There is often overlap and sometimes interchangeable terminology among patient journey, patient flow through the healthcare system, and the treatment buying process. In rare diseases, the patient journey can be even more critical, as there may be a lack of internal knowledge, published data, or even currently available treatments. Read the full post to learn more!
We’ve all heard the business adage that acquiring a new customer costs 6 – 7 times as much as retaining an existing one. But how often is that wisdom applied for pharmaceutical products? As an industry, we are often too focused on driving new patient prescriptions and forget to focus on the patients already taking our product. Average treatment duration is one of the most important metrics in evaluating sales of a pharmaceutical product and small improvements translate directly to a product’s bottom-line. Read the full post to learn more!
One of our longtime clients recently engaged with us to collect physician feedback on two diabetes-related diagnostic testing panels. Because rollout was impending, rapid insights were needed to inform their decision. To obtain nuanced information quickly, we employed a new methodology called Virtual Voice-response Interviews (VVIs). Read the full post to learn more!
Clinical trials are a significant portion of the cost to bring a new drug to market. Recent research published in Clinical Trials estimated the combined average total cost of conducting a single endocrinology clinical trial in each of Phases I, II, and III was US $30.5 million. With costs this high (and likely higher as time goes on), it’s natural to wonder if there are ways to optimize a clinical trial’s impact before committing to the substantial investment required. Fortunately, market research provides two opportunities to gauge the impact of a clinical trial through use of two designed experiment methodologies.
An estimated 12 million Americans need some form of formal, long-term care (LTC). Commonly, when our clients think about the LTC market, they focus on skilled nursing facilities (SNFs), but assisted living facilities (ALFs) and home care are equally important for many products and services.